Although NSC348884 significantly inhibited tumor growth in vivo (Supplementary Fig. 7B), it neither decreased PD-L1 expression nor increase CD8+ cell infiltration in vivo (Supplementary Fig. 7C, E). The gene discussed is CD8A; the disease is neoplasm.